Camptothecin post-treatments inhibit the biochemical events linked to the tumor-promoting component of carcinogenesis in mouse epidermis in vivo.
20(S)-Camptothecin (CPT), a topoisomerase I inhibitor specifically toxic toward S-phase cells, was tested topically for its ability to inhibit the biochemical markers of skin tumor promotion. CPT has no or very little inhibitory effect on the covalent binding of an initiating dose of 7,12-dimethylbenz-[a]anthracene (DMBA) to DNA at 24 hr, but CPT post-treatments remarkably inhibit stimulations of DNA synthesis caused by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) at 16 hr and a carcinogenic dose of DMBA at 7 days. CPT is a much more potent inhibitor if it is applied 10-14 hr after TPA or 4-6 days after DMBA, when DNA synthesis starts being stimulated after the periods of early inhibition caused by TPA and DMBA. When applied 12 hr after the tumor promoter, the ability of 3-3,000 nmol of CPT to inhibit TPA-stimulated DNA synthesis at 16 hr is dose-dependent. A single dose of 500 nmol of CPT inhibits the entire time course for the stimulation of DNA synthesis observed 16-64 hr after TPA. CPT also reduces the various DNA responses to chronic TPA treatments and structurally different non-TPA-type tumor promoters. CPT may indirectly decrease the ornithine decarboxylase-inducing activity of multiple TPA treatments because it can inhibit the stimulation of RNA synthesis by this compound. However, CPT fails to alter TPA-stimulated hydroperoxide production in relation to its inability to inhibit TPA-stimulated protein synthesis. On an equal dose basis, topotecan and 10-hydroxycamptothecin are more and less effective than CPT, respectively, whereas 10,11-methylenedioxycamptothecin is much more potent than its parent compound at inhibiting the DNA response to TPA. A single dose of 400 nmol of CPT has no effect on tumor initiation when applied 4 hr before or 1 hr after a single subcarcinogenic dose of DMBA. In contrast, 400 nmol of CPT chronically applied 1 hr before or 24 hr after each treatment with TPA remarkably inhibits the complete tumor-promoting activity of this agent. CPT post-treatments also inhibit the respective activities of TPA and mezerein in the 1st and 2nd stages of skin tumor promotion.
Gao
X M
XM
Anti-Cancer Drug Laboratory, Division of Biology, Kansas State University, Manhattan, KS 66506-4901, USA.
Perchellet
E M
EM
Davis
A W
AW
Newell
S W
SW
Chen
G
G
Hua
D H
DH
Perchellet
J P
JP
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000737:chemistry; D000818:Animals; D002166:Camptothecin / Q000008:administration & dosage* / Q000031:analogs & derivatives; D004247:DNA / Q000096:biosynthesis; D018736:DNA Adducts / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004790:Enzyme Induction / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004817:Epidermis / Q000378:metabolism; D005260:Female; D051379:Mice; D009955:Ornithine Decarboxylase / Q000378:metabolism; D012878:Skin Neoplasms / Q000139:chemically induced*; D013329:Structure-Activity Relationship; D013755:Tetradecanoylphorbol Acetate / Q000037:antagonists & inhibitors*; D059004:Topoisomerase I Inhibitors
D018736:DNA Adducts; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D015127:9,10-Dimethyl-1,2-benzanthracene; D004247:DNA; D009955:Ornithine Decarboxylase; D013755:Tetradecanoylphorbol Acetate; D002166:Camptothecin